Status:

NOT_YET_RECRUITING

Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis

Lead Sponsor:

Universidad Industrial de Santander

Collaborating Sponsors:

Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle

Conditions:

Cutaneous Leishmaniasis

Cutaneous Leishmaniasis, American

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The goal of this clinical trial is to learn if the drug MILTEFOSINE, used topically in a hydrogel, works to treat non-complicated cutaneous leishmaniasis (CL) in adults. It will also learn about the s...

Detailed Description

Study universe/study population It is the department of Santander in Colombia. The department ranks third in Colombia for the highest number of CL cases, with an incidence of 57% of cases per 100,000 ...

Eligibility Criteria

Inclusion

  • Diagnosis of confirmed cutaneous leishmaniasis (CL)
  • Age: 18 - 65 years.
  • Patients who have 1-4 CL skin lesions with a diameter of 1-4 cm, with an evolution time of more than one month and not located on the face, ears, or joints.
  • Patients WITHOUT suspected complicated CL (large regional lymphadenopathy, several large lesions spread to different parts of the body); NO mucosal leishmaniasis and NO suspicion of unusual leishmaniasis syndromes (e.g., recurrent leishmaniasis, diffuse or disseminated CL).
  • Patients with NO history of systemic antileishmania treatment within 8 weeks prior to starting the study.
  • Patients WITHOUT treatment failure with local therapy (intralesional antimonial injections or thermotherapy) or systemic therapy.

Exclusion

  • Pregnant or lactating women; women of reproductive age who refuse to use contraception until 45 days after treatment ends.
  • Patients with cardiovascular, hepatic, or renal impairment or who report underlying diseases that medically compromise their participation in this study.
  • Patients who report a history of immunodeficiency.

Key Trial Info

Start Date :

January 1 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 30 2026

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT07149753

Start Date

January 1 2026

End Date

August 30 2026

Last Update

September 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Calle 158 No. 20-95 Cañaveral

Floridablanca, Santander Department, Colombia